55
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Monkeypox outbreaks outside endemic regions: scientific and social priorities

      discussion

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As the world recovers from the shock of the COVID-19 pandemic and reflects on lessons learnt from failure of global public health systems to contain the global outbreak of SARS-CoV-2, 1 new infectious disease threats, caused by movement of people globally, remain omnipresent, and repeated calls 2 for more proactive action go unheeded. This is aptly shown by the unprecedented and unexpected outbreaks of human monkeypox cases and clusters since May 7, 2022, across Europe, the Americas, and Australia, 3 which yet again, have taken global public authorities by surprise. In the ongoing outbreak, the first monkeypox case reported by the UK Health Security Agency on May 7, had travel links to Nigeria. 4 On May 14, two more cases were identified in the UK, both lived in the same household but had no travel history to Africa and no contact with the case reported on May 7. Additional monkeypox cases have continuously been reported to WHO from 12 member states across three WHO regions. As of May 21, 2022, there have been 92 laboratory-confirmed cases and 28 suspected monkeypox cases reported to WHO from the UK, the USA, Canada, France, Germany, Belgium, Spain, Portugal, Italy, Sweden, and Australia. 3 Detection of more cases is anticipated. The epidemiological links between these cases remain to be defined. Fortunately, there have been no deaths reported to date. However, there are several unusual, atypical, and perplexing aspects of these outbreaks that are of major scientific, public health, and social concern. First, the number of monkeypox cases detected in this outbreak 2 weeks since first case detection 3 in the UK alone has, by far, surpassed the total number of cases detected in the UK 5 and outside monkeypox-endemic Africa zones 2 since the first discovery of monkeypox in 1970 as a human pathogen. The scientific, environmental, and social reasons for this phenomenal increase remain an enigma and require urgent delineation through a unified, universal One Health (human, environmental, and animal) approach. 2 Second, it is very unusual and worrying that ongoing epidemiological investigations to date have revealed no substantial travel links of the cases to monkeypox-endemic areas in Africa.2, 3 This could indicate that the monkeypox virus might already have been spreading undetected in Europe for a while, with human-to-human transmission occurring due to close physical contact with infected asymptomatic or symptomatic people. Third, whether these events are due to change in monkeypox virus transmission properties or increased virulence remains unknown. Compared with RNA viruses, the monkeypox virus is a large DNA virus, which makes itself more stable and efficient than RNA viruses at detecting and repairing mutations. Thus, it is unlikely that the virus has evolved to increase human transmission. Preliminary genomic sequence data indicate a relationship with monkeypox clades circulating in west Africa, which cause milder disease and have a lower death rate than clades in central Africa. 3 Fourth, most monkeypox cases have been detected in men who have sex with men 3 and some cases in Europe occurred in men who have sex with men and bisexual men who travelled to recent festivals. Whether monkeypox is sexually transmitted requires further careful study in all geographical settings. Clusters of viral infections can occur in any group in close contact at mass gathering events. 6 The intense public and social media coverage regarding the spread of monkeypox in these contexts has generated hype in its various forms through use of language, conversation, and content, indirectly or directly negatively generating homophobic and racist stereotypes that exacerbate stigma. 7 This is prejudicial, unfair, stigmatising, and unacceptable.7, 8 Lessons from the HIV and AIDS response showed that stigma and blame undermines outbreak response, 8 highlighting the universal need for building human-rights-based, non-stigmatising outbreak responses and community-led epidemic prevention programmes. Fifth, the monkeypox outbreaks expose major gaps in understanding the dynamics of viral transmission and continuously evolving epidemiological characteristics of the disease,2, 5, 9 and a more coordinated approach to epidemic preparedness is long overdue.1, 2 Most monkeypox cases in the current outbreak are in men aged 20–50 years. Smallpox vaccination was discontinued worldwide in the 1980s and cases of monkeypox in Africa were comparatively small before this.2, 9, 10 This increase in numbers in this age group might reflect the loss of cross-protective immunity to monkeypox from not receiving the smallpox vaccination.2, 10 The antiviral tecovirimat for treatment of seriously ill monkeypox cases, and the third-generation smallpox vaccine Imvanex (Bavarian Nordic, Hellerup, Denmark) for use as prophylaxis in all close and high-risk case contacts, together with specific guidelines for their use, need to be made available urgently universally at affordable cost. Sixth, the appearance and rapid spread of monkeypox in Europe has generated intense scientific, political, and media activity. The rapid pace of developments, increasing case-detection rates, and accumulating real-time evolving data from global public health authorities have fuelled public anxieties. Two-way communication on monkeypox-related risks and engagement of affected communities on prevention, detection, and care becomes important for preventing further spread of monkeypox. Seventh, in nature, the monkeypox virus transmits to humans from either rodents or from infected humans. Hundreds of cases of human monkeypox are detected in west and central Africa annually. The few cases seen outside Africa have all been associated with travel to Africa or contact with imported infected rodents.2, 5, 9 The role of rodents in the UK monkeypox cases with history of travel to Africa4, 5, 9 might reflect the current wave of human monkeypox infections occurring in Nigeria consequential to increased exposures to rodents during the COVID-19 lockdown periods. These secondary epidemiological cycles with human-to-human spread might be affecting international travellers. Further study on rodent dynamics and monkeypox cases inside and outside endemic regions aligned to viral genomics is required to detect possible drivers for the current monkeypox epidemic. Priority for the current monkeypox outbreak should be on stopping further spread and protecting frontline health-care workers, and those most at risk globally. The unprecedented manifold increase in monkeypox cases seen in the past 3 weeks outside Africa yet again highlights that developing effective capacity at source is crucial for effective global public health preparedness and surveillance for zoonotic threats to global health security.1, 2 Rapid garnering of financial and political support for this is required to fuel reassurance, rather than fear and stigmatisation. © 2022 iStock/Biod 2022 AZ, NH, DA, FN, and RK are members of the Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Diseases Epidemics funded by the European and Developing Countries Clinical Trials Partnership, which is supported by Horizon 2020, the EU's Framework Programme for Research and Innovation. AZ holds a UK National Institute of Health Research Senior Investigator Award and is a Mahathir Science Prize and Pascoal Mocumbi Prize laureate. All authors have an interest in epidemic infections.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Clinical features and management of human monkeypox: a retrospective observational study in the UK

          Background Cases of human monkeypox are rarely seen outside of west and central Africa. There are few data regarding viral kinetics or the duration of viral shedding and no licensed treatments. Two oral drugs, brincidofovir and tecovirimat, have been approved for treatment of smallpox and have demonstrated efficacy against monkeypox in animals. Our aim was to describe the longitudinal clinical course of monkeypox in a high-income setting, coupled with viral dynamics, and any adverse events related to novel antiviral therapies. Methods In this retrospective observational study, we report the clinical features, longitudinal virological findings, and response to off-label antivirals in seven patients with monkeypox who were diagnosed in the UK between 2018 and 2021, identified through retrospective case-note review. This study included all patients who were managed in dedicated high consequence infectious diseases (HCID) centres in Liverpool, London, and Newcastle, coordinated via a national HCID network. Findings We reviewed all cases since the inception of the HCID (airborne) network between Aug 15, 2018, and Sept 10, 2021, identifying seven patients. Of the seven patients, four were men and three were women. Three acquired monkeypox in the UK: one patient was a health-care worker who acquired the virus nosocomially, and one patient who acquired the virus abroad transmitted it to an adult and child within their household cluster. Notable disease features included viraemia, prolonged monkeypox virus DNA detection in upper respiratory tract swabs, reactive low mood, and one patient had a monkeypox virus PCR-positive deep tissue abscess. Five patients spent more than 3 weeks (range 22–39 days) in isolation due to prolonged PCR positivity. Three patients were treated with brincidofovir (200 mg once a week orally), all of whom developed elevated liver enzymes resulting in cessation of therapy. One patient was treated with tecovirimat (600 mg twice daily for 2 weeks orally), experienced no adverse effects, and had a shorter duration of viral shedding and illness (10 days hospitalisation) compared with the other six patients. One patient experienced a mild relapse 6 weeks after hospital discharge. Interpretation Human monkeypox poses unique challenges, even to well resourced health-care systems with HCID networks. Prolonged upper respiratory tract viral DNA shedding after skin lesion resolution challenged current infection prevention and control guidance. There is an urgent need for prospective studies of antivirals for this disease. Funding None.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Human monkeypox – After 40 years, an unintended consequence of smallpox eradication

            Smallpox eradication, coordinated by the WHO and certified 40 years ago, led to the cessation of routine smallpox vaccination in most countries. It is estimated that over 70% of the world’s population is no longer protected against smallpox, and through cross-immunity, to closely related orthopox viruses such as monkeypox. Monkeypox is now a re-emerging disease. Monkeypox is endemic in as yet unconfirmed animal reservoirs in sub-Saharan Africa, while its human epidemiology appears to be changing. Monkeypox in small animals imported from Ghana as exotic pets was at the origin of an outbreak of human monkeypox in the USA in 2003. Travellers infected in Nigeria were at the origin of monkeypox cases in the UK in 2018 and 2019, Israel in 2018 and Singapore in2019. Together with sporadic reports of human infections with other orthopox viruses, these facts invite speculation that emergent or re-emergent human monkeypox might fill the epidemiological niche vacated by smallpox. An ad-hoc and unofficial group of interested experts met to consider these issues at Chatham House, London in June 2019, in order to review available data and identify monkeypox-related research gaps. Gaps identified by the experts included: • understanding of zoonotic hosts, reservoirs and vectors. • risks associated with transmission. • full description of the clinical spectrum and the natural history of infection including an estimation of the prevalence of monkeypox specific antibodies in humans living in areas of emergence. The experts further agreed on the need for a better understanding of the genomic evolution and changing epidemiology of orthopox viruses, the usefulness of in-field genomic diagnostics, and the best disease control strategies, including the possibility of vaccination with new generation non-replicating smallpox vaccines and treatment with recently developed antivirals.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              Mass gatherings medicine: public health issues arising from mass gathering religious and sporting events

              Summary Mass gathering events are associated with major public health challenges. The 2014 Lancet Series on the new discipline of mass gatherings medicine was launched at the World Health Assembly of Ministers of Health in Geneva in May, 2014. The Series covered the planning and surveillance systems used to monitor public health risks, public health threats, and experiences of health-care providers from mass gathering events in 2012 and 2013. This follow-up Review focuses on the main public health issues arising from planned mass gathering events held between 2013 and 2018. We highlight public health and research data on transmission of infectious diseases and antibiotic-resistant bacteria, mass casualty incidents, and non-communicable diseases, including thermal disorders. In the events discussed in this Review, the combination of a large influx of people, many from countries with outbreak-prone infectious diseases, with a high degree of crowd interactions imposed substantial burdens on host countries' health systems. The detection and transmission of antibiotic-resistant bacteria in pilgrims attending the Kumbh Mela and the Hajj raise concern of possible globalisation from mass-gathering religious events. Priorities for further investments and opportunities for research into prevention, surveillance, and management of these public health issues are discussed.
                Bookmark

                Author and article information

                Journal
                Lancet Infect Dis
                Lancet Infect Dis
                The Lancet. Infectious Diseases
                Elsevier Ltd.
                1473-3099
                1474-4457
                27 May 2022
                27 May 2022
                Affiliations
                [a ]Department of Infection, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, UK
                [b ]NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London NW1 OPE, UK
                [c ]Infectious Diseases Department, Centro Hospitalar Universitário de São João, Porto, Portugal
                [d ]The Royal Veterinary College, North Mymms, Hatfield, Hertfordshire, UK
                [e ]Irrua Specialized Teaching Hospital, Irrua, Nigeria
                [f ]Congolese Foundation for Medical Research, Brazzaville, Republic of the Congo
                [g ]Institute for Clinical Medicine, Aarhus University, Aarhus, Denmark
                Article
                S1473-3099(22)00354-1
                10.1016/S1473-3099(22)00354-1
                9141675
                35636447
                8c54e297-28b3-4da7-bfe0-cb6f52c97ba7
                © 2022 Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Comment

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article